RxDoctor Payments Data

Molly Hill, PA

Physician Assistant · Williamsville, NYNPI 1225527146

Payments from drug & device makers

$1,512in general payments, 2019–2025

Across 50 payments — averaging $30.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$470
  • Novo Nordisk$222
  • Lilly USA, LLC$219
  • Johnson & Johnson$138
  • Okami Medical, Inc.$120
  • Boehringer Ingelheim$110
  • plus $233 from 9 others

What the payments were for

  • Food & beverage$1,512100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,512 in reported general payments places this provider in the 80th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$17,190
Medicare patients
88
Services billed
242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban54$68,925
OzempicSemaglutide57$65,578
MounjaroTirzepatide48$53,612
JardianceEmpagliflozin33$44,249
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$43,501
RybelsusSemaglutide19$43,202
Breztri AerosphereBudesonide/Glycopyr/Formoterol36$29,127
XareltoRivaroxaban29$28,317
TrulicityDulaglutide22$23,308
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$17,398
Trijardy XrEmpaglifloz/Linaglip/Metformin20$16,092
MyrbetriqMirabegron11$9,475
Synjardy XrEmpagliflozin/Metformin Hcl11$7,948
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$7,046
LinzessLinaclotide13$6,435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$222$108,78076 claims
Lilly USA, LLCMounjaro, Trulicity$219$76,92070 claims
PfizerEliquis$14$68,92554 claims
Boehringer IngelheimJardiance, Trijardy Xr, Synjardy Xr$110$68,28964 claims
GSKTrelegy Ellipta$39$43,50148 claims
AstraZenecaBreztri Aerosphere$46$29,12736 claims
Johnson & JohnsonXarelto$138$28,31729 claims
AbbVieLinzess, Synthroid$470$8,12535 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →